HCPLive
American Association for the Study of Liver Diseases 2012

American Association for the Study of Liver Diseases 2012 | AASLD 2012

The American Association for the Study of Liver Diseases 63rd Annual Meeting, also known as The Liver Meeting ®, “is the largest gathering of hepatologists in the world, providing unparalleled access to groundbreaking research, new treatment guidelines, and the latest advances in the field of hepatology.” This year’s meeting will be held in Boston, Massachusetts, November 9-13. The main website for The Liver Meeting ® says that, for some clinicians, this conference “is the forum for an elite group of liver specialists to discuss and debate the year's most relevant, cutting-edge research. For others, it is a series of courses and workshops for clinicians to learn the most effective ways to treat their patients.

Conference Coverages

Combination of Faldaprevir, Non-nucleoside Inhibitor,  and Ribavirin Achieves High SVR12 in HCV
Combination of Faldaprevir, Non-nucleoside Inhibitor, and Ribavirin Achieves High SVR12 in HCV
Study results presented at The Liver Meeting 2012 show the experimental treatment leads to high rates of viral clearance in patients with hepatitis C, even in those with compensated cirrhosis.
Sofosbuvir Plus Ribavirin Effective in Multiple Hepatitis Genotypes
According to study results presented at The Liver Meeting 2012, combination treatment with ribavirin and the uridine nucleotide analog sofosbuvir achieved high rates of sustained viral response in a range of patients with hepatitis C.
New Research Brings Rapid Changes in the Hepatitis Treatment Landscape
The development of direct acting antivirals has led to significant improvement in treatment outcomes for many patients with hepatitis C. New research has also improved management of treatment-related anemia, helped streamline standard therapy, and identified promising new approaches to interferon-free treatment.
Treatment with Direct-acting Antivirals Achieves Sustained Virologic Response in Patients with Hepatitis C
Study results presented at The Liver Meeting 2012 show that administering two direct-acting antivirals results in a high rate of sustained virologic response in patients with hepatitis C who failed previous treatment with ribavirin/peginterferon.
Hyponatremia in Cirrhotic Patients Often Goes Untreated
Hospitalized patients with cirrhosis who also have hyponatremia often receive no treatment, or ineffective treatment, and are often discharged with their serum sodium too low.
New Interferon-free Treatment Options for Patients with Hepatitis C
Data presented at The Liver Meeting show that treatment with a combination of three direct-acting antivirals plus ribavirin achieved virus control in almost all patients with hepatitis C in a phase II study.
Can Alcohol Consumption Be Recommended in Patients with Liver Disease?
Study results presented at The Liver Meeting (AASLD 2012 annual meeting) show that consuming small amounts of alcohol can have net positive cardiovascular health benefits for some patients with non-alcoholic fatty liver disease.
Arrival of Protease Inhibitors Offers Hepatitis C Patients New Options, New Questions
Boceprevir and telaprevir offer improved clinical benefits to patients with hepatitis C, but a variety of racial, genetic, and other biological factors can influence treatment outcomes.
Tenofovir Monotherapy Effective in Lamivudine-resistant Chronic Hepatitis B
Study results presented at The Liver Meeting (2012 AASLD annual meeting) show that treatment with tenofovir disoproxil difumarate is safe and effective in this patient population.

Most Popular

@MDMagazine

$vacMongoViewPlus$ $vAR$